Adenoviruses have transitioned from tools for gene replacement therapy to bona fide
vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and …

The essential goal of vaccination is to generate potent and long-term protection against
diseases. Among different vaccine modalities, prime-boost vaccine strategies could …

Recombinant adenoviruses are among the most promising tools for vaccine antigen
delivery. Recently, the development of new vectors has focused on serotypes to which the …

Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the
human population is widespread, thus hampering its clinical use. Various components of the …

ABSTRACT Recombinant adenovirus serotype 5 (rAd5) vector-based vaccines are currently
being developed for both human immunodeficiency virus type 1 and other pathogens. The …

The utility of recombinant adenovirus serotype 5 (rAd5) vector-based vaccines for HIV-1 and
other pathogens will likely be limited by the high prevalence of pre-existing Ad5-specific …

Adenovirus (Ad) vectors were initially developed for treatment of genetic diseases. Their
usefulness for permanent gene replacement was limited by their high immunogenicity …

The high prevalence of pre-existing immunity to adenovirus serotype 5 (Ad5) in human
populations may substantially limit the immunogenicity and clinical utility of recombinant Ad5 …

The recent emergence of highly pathogenic avian influenza virus (HPAI) strains in poultry
and their subsequent transmission to humans in Southeast Asia have raised concerns about …

Adenovirus is a robust vector for therapeutic applications, but its use is limited by our
understanding of its complex in vivo pharmacology. In this review we describe the necessity …